ESBATech Raises Additional CHF 23M (USD 22M), Extending Series B Venture Financing (PR Newswire)

Yahoo Finance  • Aug 7, 2008

ESBATech AG, a leading developer of antibody fragment therapeutics, today announced that the company has raised an additional CHF 23M in an extended Series B venture round to expand its development pipeline. Full Story »

Post Your Comment

separate usernames and emails with a comma

Authenticating User
Loading Global Loud3r Profile